WO1994026876A1 - Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer - Google Patents
Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer Download PDFInfo
- Publication number
- WO1994026876A1 WO1994026876A1 PCT/EP1994/000742 EP9400742W WO9426876A1 WO 1994026876 A1 WO1994026876 A1 WO 1994026876A1 EP 9400742 W EP9400742 W EP 9400742W WO 9426876 A1 WO9426876 A1 WO 9426876A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- human
- cells
- antigen
- specific
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 74
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 57
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 30
- 230000001404 mediated effect Effects 0.000 title claims abstract description 21
- 230000007815 allergy Effects 0.000 title claims abstract description 19
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 18
- 201000011510 cancer Diseases 0.000 title claims abstract description 17
- 230000008569 process Effects 0.000 title claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 9
- 208000035473 Communicable disease Diseases 0.000 title claims abstract description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 436
- 239000000427 antigen Substances 0.000 claims abstract description 126
- 108091007433 antigens Proteins 0.000 claims abstract description 123
- 102000036639 antigens Human genes 0.000 claims abstract description 123
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 230000002062 proliferating effect Effects 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims description 149
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims description 124
- 102000047918 Myelin Basic Human genes 0.000 claims description 118
- 101710107068 Myelin basic protein Proteins 0.000 claims description 118
- 108091008874 T cell receptors Proteins 0.000 claims description 61
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 201000010099 disease Diseases 0.000 claims description 31
- 229960000814 tetanus toxoid Drugs 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 28
- 229960005486 vaccine Drugs 0.000 claims description 27
- 239000002269 analeptic agent Substances 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 21
- 230000000735 allogeneic effect Effects 0.000 claims description 18
- 239000012472 biological sample Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 238000010370 cell cloning Methods 0.000 claims description 11
- 238000011161 development Methods 0.000 claims description 10
- 101150117115 V gene Proteins 0.000 claims description 9
- 241000282412 Homo Species 0.000 claims description 8
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 8
- 238000009007 Diagnostic Kit Methods 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 102000006386 Myelin Proteins Human genes 0.000 claims description 6
- 108010083674 Myelin Proteins Proteins 0.000 claims description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
- 210000005012 myelin Anatomy 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 239000013566 allergen Substances 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 5
- 238000012512 characterization method Methods 0.000 claims description 5
- 230000003100 immobilizing effect Effects 0.000 claims description 5
- 230000036039 immunity Effects 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 238000007747 plating Methods 0.000 claims description 5
- 102000016202 Proteolipids Human genes 0.000 claims description 4
- 108010010974 Proteolipids Proteins 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 claims description 3
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 claims description 3
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 claims description 3
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims description 3
- 230000002297 mitogenic effect Effects 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 102000000503 Collagen Type II Human genes 0.000 claims description 2
- 108010041390 Collagen Type II Proteins 0.000 claims description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 2
- 102000008072 Lymphokines Human genes 0.000 claims description 2
- 108010074338 Lymphokines Proteins 0.000 claims description 2
- 241000159243 Toxicodendron radicans Species 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 231100000617 superantigen Toxicity 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 241000720950 Gluta Species 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 description 41
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 35
- 238000010367 cloning Methods 0.000 description 29
- 230000000638 stimulation Effects 0.000 description 29
- 238000002255 vaccination Methods 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 22
- 210000000612 antigen-presenting cell Anatomy 0.000 description 21
- 238000011081 inoculation Methods 0.000 description 19
- 230000004044 response Effects 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 17
- 230000009257 reactivity Effects 0.000 description 16
- 230000012010 growth Effects 0.000 description 15
- 230000035755 proliferation Effects 0.000 description 15
- 238000009171 T-cell vaccination Methods 0.000 description 14
- 201000002491 encephalomyelitis Diseases 0.000 description 14
- 230000005867 T cell response Effects 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 13
- 238000001516 cell proliferation assay Methods 0.000 description 12
- 230000009696 proliferative response Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 11
- 230000001717 pathogenic effect Effects 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 7
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000001363 autoimmune Effects 0.000 description 7
- 239000011651 chromium Substances 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 229910052804 chromium Inorganic materials 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 101001018318 Homo sapiens Myelin basic protein Proteins 0.000 description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000001712 encephalitogenic effect Effects 0.000 description 5
- 102000054064 human MBP Human genes 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 108091054437 MHC class I family Proteins 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000005859 cell recognition Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 101150090724 3 gene Proteins 0.000 description 3
- 208000009386 Experimental Arthritis Diseases 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000030741 antigen processing and presentation Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 230000001024 immunotherapeutic effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000008844 regulatory mechanism Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 108010015133 Galactose oxidase Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 201000004982 autoimmune uveitis Diseases 0.000 description 2
- 229940037642 autologous vaccine Drugs 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229940030156 cell vaccine Drugs 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
- 208000035474 group of disease Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000007798 limiting dilution analysis Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 description 1
- 108091071337 20 family Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000501458 Cultus Species 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000055324 Myelin Proteolipid Human genes 0.000 description 1
- 101710094913 Myelin proteolipid protein Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000011509 clonal analysis Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000001031 immunopharmacological effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000011293 immunotherapeutic strategy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464839—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention is in the field of immunology, im unotherapy and immunodiagnosis. More specifically, the invention is directed to highly proliferative and antigen-specific T-cell monoclones and a process for its production and its use for the treatment and diagnosis of infectious diseases, autoimmune diseases, T-cell mediated allergies and cancer.
- the immune system protects the host against foreign intruders (antigens) or harmful agents. It is regulated in a sophisticated network, comprising among others T cells and B cells which are programmed to carry out specific tasks. An inappropriate functioning of the immune system can lead to an immune deficiency, as observed in AIDS, or to a norn balanced immune regulation, as observed in autoimmune diseases. T cells play a major role in the control of the immune system. Many immune-related diseases known to-day are associated with a deficient or abnormal T cell function.
- Autoimmune diseases are a group of diseases sharing a common feature, that is, a deficit in the immune regulation of autoreactive T cells, (reviewed by Brostoff et al. eds. Clinical Immunology, Gower Medical Publishing, London-New-York, 1991) .
- human autoimmune diseases include Graves' disease, multiple sclerosis (MS) , rheumatoid arthritis (RA) , Myasthenia gravis (MG) , type I diabetes etc.
- autoreactive T cells or B cells producing autoantibodies are activated and clonally expanded to mount an attack on target tissues of the host.
- the process often leads to a recruitment of inflammatory cells, including macrophages, gamma delta T cells and T cells capable of producing inflammatory cytokines, followed by a destruction of the tissues involved (reviewed in Deodhar et al., Clin. Biochem. 25, 181, 1992).
- Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system, characterized by infiltrations of T lymphocytes and macrophages into white matter of the brain and by locally produced inflammatory cytokines and antibodies in the central nervous system (Selmaj et al., Ann. Neurol. 23, 339, 1988; Cross et al. , J. Neuroimmunol. 33, 237, 1991). These processes are associated with de yelinations and neurological dysfunctions. Most often the infiltrating cells are autoimmune in nature and they act as effectors in a process whereby self proteins are recognized and myelin tissue is destroyed. Autoimmune mechanisms mediated by autoreactive T cells hold a central position in a cascade of events leading to demyelination (Reviewed in Zhang et al., Intern. Rev. Immunol. 9, 183, 1992).
- EAE Experimental Autoimmune Encephalomyelitis
- MBP Proteolipid Protein
- MS is an inflammatory autoimmune disease mediated by autoreactive T cell responses to myelin antigens
- TCR T cell receptor
- MHC Major Histocompatibility Complex
- Activated MBP-specific T cells when rendered non virulent, can prevent and treat EAE in experimental animals (Ben-Nun et al., Nature 292, 60, 1981).
- This procedure is termed T cell vaccination in analogy with icrobial vaccinations to prevent infectious diseases. Both activation and attenuation are required for the vaccine to be effective in treating the disease. Attenuation can be achieved by either chemical modification or irradiation (Ben-Nun et al., Nature 292, 60, 1981).
- T cell vaccination has been found to be effective in preventing and treating several experimental autoimmune diseases.
- T lymphocytes have been used as vaccines to treat or prevent, in addition to EAE, Experimental Autoimmune Thyroiditis (EAT) , Adjuvant Arthritis (AA) and Experimental Autoimmune Uveitis (EAU) (Cohen, Immunol. Rev. 94, 5, 1986). Since the fine specificity of vaccination is dictated by the fine specificity of the T cell recognition, the TCR most likely is involved in the therapeutic or preventive effects. For example, two different MBP-specific T cell lines, each reactive to a different epitope of MBP, were found to vaccinate against EAE specifically induced by the particular epitope, indicating some form of anti-idiotypic immunity.
- This state involves T cell clones which can specifically proliferate in response to the vaccinating T cells, can suppress effector clones in vitro (non-specifically, presumably through release of a suppressive lymphokine) , and can adoptively transfer counter-autoimmunity in vivo.
- Such counter-autoimmunity is accompanied by suppressed delayed-type hypersensitivity (DTH) responses to the specific epitope and prevention or remission of clinical disease.
- DTH delayed-type hypersensitivity
- T-cell mediated allergies such as the nickel-mediated allergy (Kapsenberg, M.L. et al. J. Invest. Dermatol. 98, 59-63, 1992). Eliminating these allergen-specific T cells could be of benefit to reduce the disease symptoms.
- a further group of human diseases where antigen- specific T cell clones are currently applied for treatment are cancers.
- the pathogenesis of cancer remains unknown, it is generally accepted that a deficit in the host immunity against cancerous cells plays an important role in the development of malignant tumors (Miescher et al., J. Immunol. 136, 1899, 1986).
- tumor-specific T cells fail to eliminate tumor cells are unknown, current efforts are being made to develop an immunotherapy aimed at an increase of the functional capacities of tumor-specific T cells.
- tumor infiltrating lymphocytes (TIL) harbored at tumor sites attract most interest since they may represent an attempt of the tumor-bearing host to develop an immune attack against the tumor (Vose et al., Se in.
- TIL are comprised of heterogeneous populations of effector and immunoregulatory lymphocytes and monocytes (Whiteside et al., Int. J. Cancer. 37, 803, 1986). Recent evidence obtained from animal studies has shown that adoptive transfer of TIL into the tumor-bearing host is able to mediate significant anti-tumor effects or even to induce total tumor regression (Rosenberg et al., Science 223, 1318, 1986) . Similarly in humans, tumor-specific T cells can be derived from TIL preparations and are found to lyse tumor targets in an antigen specific fashion.
- TIL are isolated from surgical tumor specimens and expanded to 10 9 - 10 11 cells for adoptive transfer into a tumor-bearing recipient. Its potential application as an adoptive immunotherapy is currently being evaluated in pre-clinical studies and clinical trials (Rosenberg et al. ,New.Engl. J.Med.319, 1676, 1988) .
- T-cells that attack foreign antigens, autoantigens and tumors are immunologically important because these T-cells recognize specifically foreign antigens, autoantigens and tumors as their targets, and these specificities can be utilized for therapeutics and diagnostics of the diseases associated with a deficient or badly regulated function of foreign antigen specific T-cells, autoantigen specific T-cells and tumor specific T-cells.
- T cell cloning Difficulties in T cell cloning have been a constant challenge to all immunologists to study T cell interactions at the clonal level.
- Cloning of human T cells by specific antigens has been generally used as the conventional approach. In this technique T cells are stimulated by antigenic peptides processed and presented by antigen-presenting cells. However, it has been a general experience that this T cell activation pathway does not necessarily stimulate every single antigen-specific T cell. There are several lines of evidence suggesting that an inappropriate antigen presentation occurred during the interaction between an antigenic peptide and the T cell receptor induces clonal anergy which renders T cells unresponsive to the antigen (LaSalle et al., J. Exp. Med. 176, 177, 1992).
- a culture condition for T cell activation is difficult to optimize since it varies with the individual antigen involved and the functional characteristics of the individual clones.
- cloning of human T cells by antigen stimulation is largely hampered by a lower cloning efficiency and, therefore requires higher numbers of T cells for the cloning process. This gives rise to contamination of the clone preparation by other irrelevant cells and to poor growth characteristics.
- MBP-specific T cells This is illustrated by our attempt to clone MBP-specific T cells from the blood of human subjects by stimulation with MBP. Although these clones demonstrated clonal responses to a single antigenic peptide and expressed a single phenotype, PCR analysis revealed multiple V/3 gene products, indicating the oligoclonal nature of the clone preparation (Ben-Nun et al., Proceedings of National Academy of Science, 1991). These MBP-specific T cell "clones” usually maintain reactivity to MBP for a short period of time (usually two or three weeks) and subsequently deteriorate in culture. It is likely that repeated stimulation with the antigen induces unresponsiveness of the "clones” by down regulation (LaSalle et al., Journal of Experimental Medicine, 1992) .
- T cell clone is ambiguously based upon the completion of a cloning process, usually with a lower cloning efficiency, and the antigen reactivity of the "clone” preparation.
- the lack of proof for a unique genetic marker of the clone has added to the suspicion on the true clonality of these "clones” as described in many earlier publications, even though this may not directly affect their experimental outcome. Due to the advances and the implementation of molecular biotechnology, in particular the PCR techniques, in T cell cloning procedures it has been possible to provide more evidence for the monoclonality of a particular cell preparation.
- the present invention relates to a population of human T cell monoclones which is highly proliferative in the presence of an antigen to which human T cells forming this population are specific.
- the population of human T cell monoclones is characterized by its full biological purity in that it remains free of contaminating cells at all stages of subsequent culture development.
- the human T cell monoclone population of the present invention is characterized in that it gives rise to a single TCR V gene expression. It is also characterized in that it possesses a unique TCR V-D-J DNA sequence. Also preferred are T cell monoclone populations comprising cells of either the CD4 or the CD8 phenotypes.
- the antigen for which the human T cells of the population of human T cell monoclones of the invention are specific and in the presence of which the population is proliferative is preferably a tumor cell or an immunogenic portion thereof, an auto-antigen.
- Preferred other antigens include Myelin antigens or immunogenic portions thereof, particularly the Myelin basic protein, the proteolipid protein, the Myelin- associated-glycoprotein, the Myelin-Oligodendrocyte- Glycoprotein and/or mixtures thereof, more particularly an epitope of the 84-102 region or the 149-170 region of the a ino acid sequence of Myelin Basic Protein.
- the antigen to which the human T cells forming the population of human T cell monoclones are specific can also be a foreign antigen such as a Tetanus Toxoid antigen or an allergen that is mediating the allergy through T cells.
- Also within the scope of the present invention is a method for the production of a population of human T cell monoclones which is highly proliferative in the presence of the antigen to which the human T cells are specific and/or any other T cell stimulating agent, and which is characterized by its full biological purity in that it remains free of contaminating cells at all stages of subsequent culture developement.
- the method comprises:
- the human T cell line used in the method of the present invention is taken from peripheral blood lymphocytes.
- the T cell stimulating agent it is preferably selected from the group consisting of lectines, preferably PHA and/or ConA, lymphokines, preferably Interleuken-2 (IL-2) and/or a recombinant IL-2 (r-IL2) mitogenic antibodies against CD3 and other cell surface molecules and/or a mixture thereof.
- a homogeneous population of T cell receptors from human T cell monoclones forming the population of the present invention or the antigen- specific portion thereof and/or a mixture of selected populations or portions.
- a therapeutic agent for the treatment of autoimmune diseases, T-cell mediated allergies, infections and cancer comprises an effective amount of a population or a mixture of selected populations of T cell monoclones according to the invention.
- the invention also relates to a vaccine composition for conferring upon humans active immunity against other immune diseases.
- the vaccine composition comprises an effective amount of a homogenous population of T cell receptors from human T cell monoclones according to the invention or a mixture of selected populations of T cell receptors obtained from the population of human T cell monoclones according to the invention or an antigen-specific portion thereof.
- a method for the treatment of a patient suffering from a condition caused by one or more antigens associated with this condition and obtainable from a biological sample of the patent comprises vaccinating the patent with an adoptively transferring to the patient an amount of a human T cell monoclone population sufficient to generate the appropriate immune response to at least partially alleviate the condition.
- the human T cell monoclone population is responsive to the antigen and has a full biological purity in that it remains free of contaminating cells at all steps of culture development.
- the invention also relates to a kit for preparing a population of human T cell monoclones which is highly proliferative in the presence of the antigen of the type which may be held responsible of a particularly diagnosed disease and for the subsequent preparation of a population of the identified T cell monoclones.
- the kit comprises:
- the invention also relates to a diagnostic kit which comprises an appropriate solid support for immobilizing a biological sample containing a specific T cell responsive to an antigen associated with the condition to be diagnosed, means for at least immobilizing the specific T cell on the support and an antibody to a T cell monoclone receptor specific for the antigen associated with the condition to be diagnosed.
- the population of human T cell monoclones of the present invention is particularly useful to maintain T cell monoclones in a long term culture in order to reach a sufficient amount of cells to prepare appropriate therapeutic agents.
- a diagnostic and a therapeutic agent capable in a specific manner, of detecting, preventing, suppressing and/or treating infectious and immune-related diseases and/or cancer.
- the human T cell monoclone population of the present invention can be expanded to a sufficiently high amount to be used either in a diagnostic kit or as a therapeutic agent, such as a vaccine or a preparation of T cells to be used for adoptive immune therapy.
- a therapeutic agent such as a vaccine or a preparation of T cells to be used for adoptive immune therapy.
- the human T cell monoclone population can also be used as a therapeutic agent to prevent, suppress and/or treat infectious and immune-related diseases and/or cancer, without causing generalized suppression of immunity as it is the case with most current immuno-therapeutic and immuno-pharmacological approaches of the state of the art.
- the present invention also provides a method for the in vitro preparation of foreign antigen specific, autoantigen specific and tumor specific T cell monoclone populations which minimizes or even eliminates the problems of contaminating cells associated with current methods of the state of the art.
- Figure 1 illustrates the reactivity pattern of a panel of MBP-specific T cell lines to three MBP fragments.
- Figure 2 represents the PCR analysis of TCR V/3 gene usage of MBP-specific T cell clones cloned by repeated MBP stimulation (panel A-B) and by PHA stimulation (panel C-D) .
- Panel E represents single V ⁇ gene usage of a typical TSL clone cloned by the method of the invention.
- Figure 3 illustrates a comparison of the cloning efficiencies of MBP-specific T cell lines by PHA and MBP stimulation.
- Figure 4 represents the proliferative responses to the inoculates and control T cells and the changes in the frequency of MBP-specific T cells before and after each inoculation.
- Figure 5 represents the relationship of changes in the frequencies of T cells reactive to MBP, TT and inoculates in recipients (GE and CW) and non- recipients (AH and GC) .
- Figure 6 represents the functional properties of the anti-clonotypic T cell lines.
- Figure 7 represents the proliferative response of TSL lines to autologous and allogeneic tumor targets.
- Figure 8 represents the cytotoxic activity of the TSL lines against autologous and allogeneic tumor cells, NK-sensitive K562 cell line, and NK-resistant Daudi cell line.
- the MCF7 cell line is a human breast cancer line.
- Figure 9 represent the anti-clonotypic T cell responses to vaccine clones and changes in the estimated frequency of circulating MBP-reactive T cells in six patents with MS, before and after each inoculation.
- Figure 10 is a schematic representation of the TCR gene organization and the specific sites within the target TCR potentially eliciting the anti- clonotypic T cell responses.
- the invention relates to antigen-specific T- cell monoclonal populations and their use in diagnosis and treatment of various diseases such as infectious diseases, autoimmune diseases, T-cell mediated allergies and cancer.
- Clonotypic regulation is one of the important components of peripheral regularotry mechanisms that keep autoreactive T cells in check.
- This regulartory network can be boosted by T cell vaccination to therapeutically deplete autoaggressive T cells in autoimmune pathologies, resembling traditional vaccination using attenuated autoreactive T cells as vaccines.
- cellular and molecular interactions potentially involved in the clonotypic regulatory network result in therapeutic applications of T cell vaccination in human autoimmune diseases, such as multiple sclerosis.
- Autoreactive T cells recognizing a variety of self-antigens represent part of the normal T cell repertoire and naturally circulate in the periphery.
- autoreactive T cells undergo activation and clonal expansion, which represents the hallmark of the pathologic properties of autoaggressive T cells in the induction of autoimmune diseases.
- Activation of autoaggressive T cells renders them to acquire a different functional state and a homing pattern into the affected organ.
- Clonal expansion features not only an increase of autoaggressive T cells in their numbers but also a shift of their normally heterogeneous T cell receptor (TCR) repertoire towards an eliciting pathogenic epitope(s).
- TCR normally heterogeneous T cell receptor
- the critical transaction from autoreactivity, a normal physiological state, to autoimmune pathology relates to the interplay between activation and clonal expansion of autoreactive T cells and an improper functioning of regulatory networks that keep them in control.
- TCR hypervariable epitopes constitute clonotypic markers characteristic for an individual autoreactive T cell clone and recognizable by its regulators.
- the clonotypic interaction represents the "fine-tuning" of the regulatory network without affecting the remainder of the T cell repertoire. Recent investigations further suggest that such a clonotypic network is naturally operative in vivo and can be up-regulated in a clinical setting to therapeutically deplete autoaggressive T cells.
- autoreactive T cells are viewed as pathogens in T cell-mediated autoimmune diseases, they can be used, when rendered avirulent by irradiation or pressure and chemical treatment, as vaccines to prevent and treat the diseases.
- the principle of T cell vaccination is similar to traditional microbial vaccination against infectious agents. There is evidence that administration of attenuated autoreactive T cells as vaccines induces the regulatory networks to specifically suppress the eliciting autoreactive T cells (Ref. 7) .
- T cell vaccination is effective in preventing and treating many experimental autoimmune diseases, including experimental autoimmune encephalomyelitis (EAE) , experimental autoimmune uveitis, experimental diabetes model and adjuvant arthritis.
- EAE experimental autoimmune encephalomyelitis
- the protective effect is long-lasting and specific since the autoreactive T cells used for vaccination only protected against the disease that they are able to induce.
- CD4 + and CD8 + anti-clonotypic regulatory T cells are induced by and specifically recognize the immunizing clones.
- These anti-clonotypic T cells are .the major cellular component of the protective mechanism and are capable of conferring a specific protection to naive rats by adoptive transfer.
- Other regulatory T cells may also contribute to the protection by interacting with cellular markers other than the TCR clonotypes, such as the regulatory T cells identified as anti-ergotypic T cells that respond not to the TCR but to a marker associated with their state of activation.
- Variable TCR region(s) involved in triggering the anti-clonotypic T cell responses in vivo are most likely to reside in hypervariable regions, such as complementary determining region-3 (CDR3) or less variable CDR2 regions.
- CDR3 complementary determining region-3
- T Cell vaccination offers a unique in vivo setting in which the clonotypic network selects a relevant target epitope(s) to naturally regulate autoreactive T cells.
- FIG 10 there is provided a schematic representation of the TCR gene organization and the specific sites within the target TCR potentially eliciting the anti-clonotypic T cell responses in vivo.
- EAE activated encephalitogenic T cells are the direct cause of the disease.
- Their TCR repertoire towards Myelin Basic Protein (MBP) a causal autoantigen, is rather limited with respect of both a limited epitope recognition and the V gene usage.
- MBP Myelin Basic Protein
- the limited TCR repertoire provides suitable molecular targets for specific therapeutic interventions.
- TCR-based strategies have been developed to target at V ⁇ gene products or other attacking points within the TCR characteristic for the encephalitogenic T cells.
- V3 gene usage pattern varies largely among MS patients but it appears to be restricted in a given individual.
- Studies conducted in the context of the present invention have revealed that the limited V/3 gene usage in a given MS individual rather represents a clonal expansion of MBP-specific T cells, as evidenced by their sharing of unique V-D-J and V-J juntional DNA sequence patterns.
- An example is given in Table 4 which illustrates a limited clonal origin(s) of MBP-reactive T cells isolated from a patient with MS.
- MBP-specific T cells in MS undergo activation and clonal expansion that is marked by a skewed TCR repertoire towards a related epitope(s) and certain V gene usage. Consistent with this notion is our recent finding that in vivo activated MBP-reactive T cells often share an identical V-D-J sequence pattern with the clonally expanded population(s) in a given MS patient.
- TCR V gene products among a general MS population would considerably perplex current attempts to develop TCR V gene-based therapeutic strategies.
- a treatment agent e.g. a monoclonal antibody on a TCR peptide
- TCR V gene product(s) may be useful in one patient but is not suited for another, which hampers significantly its clinical usefulness.
- clonal expansion of very limited MBP-specific T cell populations is a rather profound feature in MS, their restricted TCR repertoire provides a uniform target structure in a given patient even though it varies between individuals.
- These clonally expanded T cells often account for more than 60%-80% of all MBP-specific T cells in a given individual with MS.
- a potential therapy may take the advantage of a predominant marker representative of clonally expanded MBP-reactive T cells but its applicability may be limited to given individuals, reflecting a dilemma in designing a suitable TCR-based therapeutic strategy.
- T cell-mediated autoimmune processes there are two principal ways to halt T cell-mediated autoimmune processes either by blocking and depleting the pathogenic T cells or by boosting pre-existing regulatory mechanisms of the host.
- a potential drawback inherent in the former approach is that it requires frequent administrations of the remedy and its therapeutic effect is often short-term and diminishes with the withdrawal of the remedy.
- T cell vaccination appears to merit its place in the development of such a therapeutic strategy for various human pathologies.
- T cell vaccination appears to merit its place in the development of such a therapeutic strategy for various human pathologies.
- these T cells bearing a uniform clonotypic marker have an obvious therapeutic potential for immune intervention.
- the T cells used in the production of the monoclone populations of the invention are selected according to the condition to be treated.
- patient peripheral blood lymphocytes are used to derive the appropriate T cell lines.
- tumor specific lymphocytes the cells are obtained from tumors excised from patients.
- T cells found in the anatomic region associated with the condition include rheumatoid arthritis for which cells associated with this condition are found in the synovial fluid of the joints, and multiple sclerosis for which associated cells are found in the cerebro-spinal fluid.
- specific cell lines can be generated from peripheral blood lymphocytes. As it will be seen from the examples which follow this description, this procedure was successfully applied to generate T cell lines specific to a Tetanus Toxoid antigen.
- the person skilled in the art can use the techniques referred to above or other methods to generate the appropriate antigen-specific cell lines.
- the person skilled in the art may also refer to the examples of the present application which provide specific procedures for generating MPB-specific T cell lines from peripheral blood, tumor specific lymphocytes from tumors excised from patients and the generation of Tetanus Toxoid specific T cell lines from peripheral blood.
- peripheral blood lymphocytes are isolated and cultured in the presence of the antigen for a period of time ranging from 5 to 10 days. This time may vary depending on the number of reactive cells in the sample, the activation state of the cells, and the potency of the stimulating preparation. All these factors can be adjusted by the person skilled in the art.
- the resulting cultures are restimulated with autologous antigen-presenting cells previously irradiated to prevent their proliferation and the antigen.
- the restimulation time may vary but will usually range between 5 and 12 days.
- it can, in some instances, be necessary to use surface-oxydized allogeneic cells to stimulate the lymphocytes periodically in the presence of an appropriate T cell stimulating agent.
- the viable T-cell lines are then isolated and restimulated with the autologous antigen-presenting cells in the presence of the appropriate antigen for a period of time ranging from 5 to 12 days.
- the cell lines are then examined for their specific proliferation in response to the antigen in a proliferation assay.
- the antigen-specific T cells are plated out at very low cell densities in the presence of irradiated autologous or allogeneic antigen-presenting cells and a potent T cell stimulating agent such as PHA and/or ConA, mitogenic antibodies against CD3 and other surface molecules and/or a mixture thereof.
- a potent T cell stimulating agent such as PHA and/or ConA, mitogenic antibodies against CD3 and other surface molecules and/or a mixture thereof.
- T cell stimulating agents set forth above are provided as examples and that other T cell stimulating agents can also be used.
- cultures can be refed with fresh culture medium containing lymphocyte growth factors such as IL-2 that can be further expanded by alternate stimulation with the antigen and the T cell stimulating agents referred to above. It is to be noted that, apart from its growth factor propertie, IL-2 can also be used as a T-cell stimulating agent.
- the single cell cloning approach is an important aspect of the present invention. Hence, it provides for higher cloning efficiencies, improved growth characteristics which allow for a large scale expansion of the clones, maintenance of antigen specificity after repeated expansions and monoclonality. In fact, with the method of the present invention, it is possible to grow a homogeneous population of several million cells in a period of time of 4 to 6 weeks. The use of a potent T cell stimulating agent avoids the contamination problems encountered with antigen-presenting cells.
- the method of the present invention allows the production of homogeneous T cell monoclone populations that can be grown in sufficient amounts to be used in therapy.
- the populations of the present invention are not restricted to cells recognizing a single immunogenic epitope or antigen. It is possible to develop cell line populations comprising mixtures of different clones that recognize different epitopes on one antigen. In such situations, it might be necessary at the beginning to conduct parallel single cell clonings in order to initially grow homogeneous populations that recognize a single epitope which can then be combined to generate the appropriate mixture.
- a highly proliferative T cell clone can be defined by its stimulation index of at least 10 (CPM in the presence of the antigen/CPM in medium only) , which is measured in a standard 3H-Thymidine uptake assay.
- Antigen-specific T cells are often tolerized after repeated antigenic challenge or by inappropriate antigen presentation.
- the invention offers a practical alternative by alternate stimulation of the clones with the antigen(s) and a non-specific stimulating agent such as PHA. This procedure ensures the specificity and responsiveness of a clone maintained in a long term culture.
- the human T cell populations developed using the method of the present invention can therefore maintain a high degree of biological purity by remaining free of contaminating cells after numerous subculturing stages. This biological purity is explained in part by the absence of other cells having the ability to grow in the presence of the antigen to which the desired human T cells are specific. In therapeutic applications, it is important to maintain uniform characteristics in the cells forming the populations in order to ensure constant treatment efficacy. Kit for the identification of human T cell monoclones and for the preparation of populations of human T cell monoclones
- the kit can be used for the identification of those human T cell monoclones which are highly proliferative to an antigen of the type which may be held responsible of a particularly diagnosed disease and for the subsequent preparation of a population of the identified human T cell monoclones.
- the equipment required for the preparation of T cell vaccines is available on site, clinicians using the kit of the present invention are able to identify, from a biological sample of a patient, specific T cells responsive to a targeted antigen associated with the condition to be treated and to isolate and proliferate these specific T cells in sufficient amounts to use them for vaccination and treatment purposes.
- the kit comprises the antigen, or an immunodominant peptide thereof, required to identify the specific T cell from the biological sample, means for plating the identified human T cell line at very low cell density and a T cell stimulating agent for growing the low density plated specific human T cell.
- Optional elements that can form part of the kit include reagents to evaluate the proliferation of the specific T cells prior to plating. The choice of these reagents is within the knowledge of the person skilled in the art.
- Antigens comprised in the kit preferably include those antigens which are common to most patients suffering from the condition to be treated. It can be the whole molecule or peptides or fragments thereof containing the relevant immunodominant epitopes. Examples of such antigens include:
- the means for plating the human T cell lines can be chosen from a relatively large number of devices which can be operated by the person skilled in the art.
- the T cell stimulating agent it can also be chosen from a wide variety of available compounds. What is required is that the T cell stimulating agent be sufficiently potent to stimulate the development of T cells plated out at very low cell densities. Available compounds include those referred to above such as PHA. However, the person skilled in the art may select other stimulating agents that would provide enhanced growth of T cells plated out at low densities.
- the antigen is not an integral component of the kit.
- the antigen-specific T cell lines are developed from biological samples which are related to the condition to be treated.
- autoimmune diseases patient peripheral blood lymphocytes are used, in tumor specific lymphocytes, cells obtained from excised tumors are used, in rheumatoid arthritis, cells found in the synovial fluid of the joints are used and in multiple sclerosis, cells found in the cerebro-spinal fluid are used.
- T cell populations of the present invention in the treatment of diseases or disorders can be accomplished by those skilled in the art using known principles of diagnosis and treatment.
- One important criterium is that the T cell clone population selected must have good growth characteristics, which permits large scale expansion of the clones to a sufficient amount that can range between 1 x IO 6 and 1 x IO 8 cells per clone.
- compositions are prepared using inactivated cells or by combining inactivated cells to the appropriate carrier, which itself can be an immunological adjuvant.
- These compositions can be administered by any means that achieves the intended purpose.
- administration may be subcutaneous, intravenous, intradermal, intramuscular or intraperitoneal.
- the amount of cells administered as well as the frequency of administration is dependent upon the age, sex, health and weight of the recipient as well as the nature of the effect desired.
- between 1 x IO 5 and 5 x IO 7 cells can be injected in at least 2 inoculations.
- the amount of cells administered should be sufficient to induce a substantial proliferative response to the vaccine preparation, preferably after the second inoculation.
- a pool of 10 7 -1.5 x IO 7 irradiated cells can be prepared as a vaccine and injected subcutaneously.
- the selection of the amount of cells for vaccination can be made on the basis of an effective dose in humans such as described in Zhang et al. Science Vol 261, p. 1451-1454 (1993) or on the basis of an appropriate animal model such as the model described by Ben-Nun et al. in 1981, Nature 292, 60-63.
- the number of inoculations necessary to induce the appropriate proliferative response against a particular vaccine clone or a mixture of clones can vary depending on the type of disease, disease state and the immunological state of the patent. Generally, for autoimmune diseases, at least two inoculations of 10 7 -1.5 x 10 7 irradiated cells administered at 2 to 4 months intervals is sufficient to generate the appropriate response. In some situations, the number of inoculations needed can be higher dependent on the short and long term immune response of the patient to the specific T-cell vaccine and the antigen specificity of other possible pathogenic T-cells involved in the disease mechanism.
- the response of the patient to the treatment is evaluated by analyzing the proliferation of anti- clonotypic T cells in patients injected with the T cell population of the invention. Briefly, peripheral blood mononuclear cells are isolated from the patient at different intervals following inoculation and plated out for stimulation to the targeted antigens. If the patient has responded to the treatment, specific regulatory T cells are detectable in the patient. Normally, either CD4+ or CD8+ cell lines are stimulated by the inoculates. However, it is possible that other T cell populations are also induced by the vaccination, not only by exhibiting an inhibitory effect toward the vaccination product but also by driving the regulation network to enhance the suppression.
- the T cell monoclone population of the present invention can also be used in the diagnosis of conditions which result from the pathogenic role of these cells.
- a biological sample, or a lysate thereof, taken from the patient is immobilized on a solid support.
- the presence of a particular pathogenic T cell is then determined by applying a monoclonal antibody directed against a recognized shared sequence of the T-cell receptor. Identification can be performed by various immunostaining techniques such as ELISA and flow cytometry, a well known procedure to those skilled in the art.
- the diagnostic kit of the invention therefore comprises a solid support on which the biological sample can be deposited and the relevant T-cells immobilized. It also includes means for at least immobilizing the sample cells on the support.
- means for at least immobilizing the sample cells on the support include the attachment of the cells on ELISA plates with antibodies (see for example Lymphocytes: a practical approach, Ed. Klaus GGB, pp. 48-54 1987 IRL Press, Oxford, Washington D.C.) or chemical cross-linking (see for example 1990 Anticancer research 10, 271-278).
- the kit also comprises a monoclonal antibody or monoclonal antibodies to a specific T cell membrane receptor recognizing one of the antigens associated with the condition to be diagnosed.
- the antibodies can be obtained by methods known to those skilled in the art. See for example Kohler and Milstein, Nature 256: 495-497, 1975 and US patent 4,376,110. Such antibodies can be of any immunoglobulin class but are preferably of the IgG class.
- Antibodies can also be prepared from polyclonal antiserum taken from animals immunized with the human T cell monoclone population of the present invention and subjected to various purification techniques known by those skilled in the art.
- the antibodies used can be labelled with an enzyme, a fluorescent dye or a fructoluminescent label as is well known to those skilled in the art.
- the antibodies can be labelled with a DNA fragment that can be amplified by PCR as has been described previously (Sano T et AL. Science, Vol. 259, p. 120-122, 1992).
- Monoclonal antibodies of animal origin or fragments thereof or recombinant antibodies containing the antigen binding region of the original antibody can be "humanized” by linking a cDNA molecule encoding the region of the monoclonal antibody to DNA encoding the human constant region, using various approaches described for example in US patent 4,816,567, European patent publication EP 125023, EP 171496 and EP 173494 and PCT publication WO 8601533 and WO 8602671.
- An example of the diagnostic kit of the invention is one to be used in the diagnosis of multiple sclerosis.
- Monoclonal antibodies to shared T cell monoclone receptors specific to immunodominant regions of MBP are prepared and fixed on an appropriate support.
- a biological sample taken from a patient suspected of suffering from multiple sclerosis is then contacted with the support.
- the positive binding of T cell receptors to the support indicates the presence of T cells specific for immunodominant MBP epitopes in the biological sample.
- MBP-specific T cell monoclone a. Generation and characterization of MBP-specific T cell lines.
- PBMC Peripheral blood mononuclear cells
- Ficoll density gradient separation Zhang et al., Cell. Immunol. 139, 118, 1992. This method comprises following steps : diluted blood is overlaid on Ficoll and centrifuged at 1,800 rpm for 20 min. Subsequently the PBMC are washed three times and resuspended to a homogeneous suspension. PBMC are then plated out by limiting dilution (Zhang et al., Ann. Neurol.
- Human MBP is extracted from the white matter of human brain tissue and purified by column chromatography (Hashim et al., J. Neurosci. Res. 16, 467, 1986) . These conditions were optimized, in a set of experiments involving more than 50 clinical blood samples, to give a maximal T cell response. Cultures were maintained in an incubator conditioned with 5% C02 and 37°C for 7 days. After 7 days, cultures were restimulated with 100,000 /well irradiated autologous PBMC pulsed with MBP. Pulsing of PBMC was carried out by incubating PBMC with 100 ⁇ g /ml of MBP at 37°C for four hours. Free MBP was washed away prior to irradiation of the cells.
- MBP-specific T cell lines were performed at Day 12 and Day 14 in a proliferation assay. Each culture was split into four aliquots (approximately 10 4 cells per aliquot) and cultured in duplicates in the presence of 10 5 autologous PBMC pulsed or non pulsed (control) with MBP for 72 hours. 1 ⁇ Ci/well of 3 H-thymidine was added during the last 16 hours of cultu eand the cells were collected with the use of a cell harvester (Betaplate 1295-004, Pharmacia) . Tritiated thymidine uptake was measured in a beta scintillation counter (Betaplate 1205, Pharmacia) .
- the frequency of MBP-specific T cells was calculated according to the Poisson statistics (Lefkovits et al. eds. Limiting dilution analysis of cells in the immune system. Cambridge, Cambridge University Press, 1979; Fey et al. J. Exp. Med. 158, 40, 1983) . Briefly, a culture was scored positive if its mean CPM was greater than 1,000 and if the CPM were at least three times higher than the control CPM, a frequency of positive wells was obtained at each cell concentration.
- MBP-specific T cells occur at an estimated frequency between IO '7 and IO "6 in peripheral blood lymphocytes both in patients with MS and controls (Zhang et al., Ann. Neurol. 32, 330, 1992; Ota et al.. Nature 346, 183, 1990).
- Culture medium used was RPMI 1640 supplemented with 10% autologous serum (heat-inactivated at 56°C for 30 min.), 2 mM L-glutamine, 50 ⁇ g/ml gentamicin, (Gibco, Life Technologies) , and 10 mM Hepes buffer (Flow Laboratories, Belgium) .
- MBP-specific T cell lines were plated out at 10,000 cells per well and restimulated with irradiated autologous APC pulsed with MBP. 7 days later, the cell lines were re-examined for their specific proliferation in response to MBP in a proliferation assay (described above) .
- An example is given in Table I to illustrate the procedure.
- MBP- specific T cell lines were further examined for phenotype expression and reactivity to the MBP fragments and synthetic peptides as shown in Figure 1A-1B.
- PBMC or B cells were incubated with 2 to 5 ⁇ g/ml of a peptide or a peptide mix for four hours and washed two times before irradiation. Specific proliferative response to a fragment or peptide was measured in a proliferation assay.
- T cell responses to MBP in humans are restricted to the CD4 phenotype and directed predominantly to two immunodominant epitopes on MBP.
- One is located within the 84-102 region and the other resides in the 149-170 region (Reviewed in Zhang et al., Intern. Rev. Immunol. 9, 183, 1992).
- Reactivity to these two immunodominant epitopes accounts for more than 60% of the T cell responses to MBP (Zhang et al., Ann. Neurol. 32, 330, 1992; Ota et al. , Nature 346, 183, 1990; Pette et al. , Proc. Natl. Acad. Sci. 87, 7968, 1990).
- Table I shows an example of a general scheme used to establish MBP-specific T cell lines from PBMC.
- Figure 1 illustrates the reactivity pattern of a panel of MBP-specific T cell lines to three MBP fragments, spanning 1-38, 45-89 and 90-170 regions of human MBP ( Figure 1A) and to synthetic peptides overlapping the 84-171 region of MBP ( Figure IB) .
- Figure 1A Single-cell cloning of MBP-specific T cells:
- a true clone usually gives rise to a single expression of TCR V ⁇ gene when tested with a panel of TCR V ⁇ gene primers by polymerase chain reaction (PCR) while multiple V ⁇ gene usages in a clone preparation indicates oligoclonal contamination.
- An example of such contamination is given in Figure 2 (panel A and panel B) , which shows oligoclonality after cloning at 3 cells per well. This oligoclonality is most likely caused by contaminating T cells present in an original T cell line preparation. This can be further confirmed by Poisson statistics (see Lefkovits et al. eds. Limiting dilution analysis of cells in the immune system. Cambridge, Cambridge University Press, 1979) .
- MBP-specific T cells are plated out at 0.1 cell and 0.3 cell per well in the presence of irradiated autologous or allogeneic PBMC and PHA at 0.2 to 10 ⁇ g/ml. Cultures are refed with fresh culture medium containing rIL-2 (5 units /ml) every three days. At Day 14, growth-positive clones (usually 6% - 10% positive rate) are tested for their specific response to MBP, as described above.
- MBP-specific T cell clones derived from this cloning procedure are highly proliferative to MBP and .
- other T cell stimuli including anti-CD3 antibodies (Weber et al., J. Immunol. 135, 2337, 1985), PHA, ConA and IL-2 and can be further expanded to more then 10 7 - 10 8 cells by alternate stimulation with MBP and PHA.
- This method has many advantages over conventional cloning methods by MBP stimulation, including (1) higher cloning efficiency, (2) improved growth characteristics, which allow for a large scale expansion of the clones with PHA or MBP stimulation, (3) maintenance of MBP specificity after repeated expansions and (4) monoclonality, confirmed by a single TCR V ⁇ gene expression ( Figure 4, panels C, D and E) .
- Figure 2 represents the PCR analysis of TCR V ⁇ gene usage of MBP-specific T cell clones cloned by repeated MBP stimulation (panel A-B) and by PHA stimulation (panel C-D) .
- Panel E represents single V ⁇ gene usage of a typical TIL clone cloned by the PHA method.
- the V/3 genes of the clones were first amplified by each of 20 family-specific primers with a standard PCR technique (35 cycles) and a particular V ⁇ gene product was then hybridized with a specific probe in a Southern blot analysis. An amplified TCR V ⁇ gene product(s) is indicated, along with molecular weight markers.
- C ⁇ refers to constant ⁇ gene products.
- Figure 3 represents the comparison of cloning efficiency of MBP-specific T cell lines by PHA and MBP stimulation (a representative experiment) .
- a MBP-specific T cell line (stimulation index 11.2) was cloned by limiting dilution at indicated cell concentrations and stimulated by MBP (left panel) or PHA (right panel) in the presence of autologous PBMC. Data are given as frequencies of growth-positive wells (open circles) and MBP-specific T cell clones (closed circles) .
- the frequency of MBP-specific T cells was estimated by the Poisson probability to be 1/250 by MBP cloning and 1/5 by PHA cloning.
- Vaccination procedure The frequency of MBP-specific T cells was estimated by the Poisson probability to be 1/250 by MBP cloning and 1/5 by PHA cloning.
- MBP-specific T cell clones for T cell vaccination is based upon two characteristics : a.
- the second criterion is that the T cell clones selected must have good growth characteristics, which permit large scale expansions of the clones to a sufficient amount (3xl0 7 -6 x IO 7 ) for a total of at least two inoculations.
- T cell clones are activated with MBP-pulsed autologous APC four days prior to inoculation and tested for common bacterial and viral contaminants (Hafler et al., Clin. Immuno. Immunopath. 62, 307, 1992) . Cells are then washed three times with sterile PBS (filtered through a filter with 0.22 ⁇ m pore size) and irradiated at 8,000 rads. For each immunization, a pool of 10 7 - 1.5 xlO 7 irradiated cells of at least two different MBP-specific T cell clones are prepared in 1 ml PBS as a vaccine and injected (5 x IO 6 cells in 0.5 ml of PBS per arm) subcutaneously.
- Table II shows the clinical data of six patients with MS who participated in the trial and the fine specificities of the MBP-specific T cell clones used for vaccination.
- Table II represents the peptide reactivity of MBP-specific T cell clones used as inoculates.
- MBP-specific T cell lines were generated from peripheral blood of the patients, as described above and cloned at 0.3 cell per well by limiting dilution with 10 5 irradiated autologous feeders and PHA (2 ⁇ g /ml) . Cultures were refreshed with culture medium containing 5 units rIL-2/ml every three days. After 12 - 14 days, growing clones were examined for their reactivity to three fragments of MBP, covering 1-37, 45-89 and 90-170 regions of MBP (provided by Dr. SH Chou) and subsequently tested with 11 peptides of MBP (provided by Dr. D. Hafler) .
- the frequency analysis of the MBP-specific T cells revealed a progressive decline of circulating MBP- specific T cells, notably after the second inoculation.
- the decrease in the frequency of MBP-specific T cells was antagonistically correlated with the magnitude of the anti-clonotypic responses ( Figure 4) .
- the frequency fell below the detectable limit of our assay in five out of six recipients at the end of the clinical trial.
- MBP-specific T cells in patient HM could still be detected after the third vaccination, but at a five f old lower frequency (1.1 x IO "7 ) than the pre- vaccination value.
- Figure 4 shows the proliferative responses to the inoculates and control T cells and the changes in the frequency of MBP-specific T cells before and after each inoculation.
- the assays were performed before vaccination and at Day 3, Week 1, Week 2, Week 4, Week 6 and Week 8 after each inoculation.
- Fresh peripheral blood mononuclear cells (PBMC) were isolated and 5 x IO 4 cells /well were cultured in triplicates with 5 x
- PBMC and irradiated inoculates or T blasts were cultured alone.
- Cell proliferations were measured by proliferation assays as mentioned above. Data are given as stimulation indices defined as the mean counts per minute (CPM) of PBMC plus irradiated inoculates or T blasts / the sum of CPM of PBMC cultured alone and CPM of irradiated inoculates or • T blasts cultured alone.
- the frequency of MBP-specific and TT-specific T cells was analyzed before vaccination and after each inoculation.
- PBMC were plated out at 2 x IO 5 cells and
- a T cell line was defined "specific" when the ratio of the CPM of wells containing MBP- or TT-pulsed APC / CPM of control wells exceeded 3 and if ⁇ CPM was larger than 1,000.
- the frequency of antigen-specific T cells was estimated by dividing the number of specific wells by the total amount of PBMC plated out.
- Figure 5 represents the relationship of changes in the frequencies of T cells reactive to MBP, TT and inoculates in recipients (GE and CW) and non- recipients (AH and GC) .
- the frequency analysis of MBP- and TT-specific T cells is described above.
- To estimate the frequency of T cells responding to the inoculates freshly isolated PBMC were plated out at 4xl0 4 and 2 xlO 4 cells per well and cultured with 4xl0 4 irradiated inoculates. After 7 days, cultures were restimulated with the irradiated stimulator (vaccine) and supplemented with rIL-2 (5 units /ml). At Day 14, 50% of each culture was taken out respectively and irradiated at 8,000 rads.
- vaccine the irradiated stimulator
- rIL-2 5 units /ml
- Cells were then split into four aliquots and added in duplicate to culture wells containing 10 4 inoculates or TT-specific T cells and 10 5 irradiated APC pulsed with MBP or TT in proliferation assays to measure their inhibitory effect.
- the inhibition was measured as 1 - (proliferation in the presence of irradiated responding T cells as inhibitor / proliferation in the absence of the inhibitor) x 100%.
- Cultures exerting more than 60% inhibition on the proliferation of inoculates were considered as responding cell lines.
- the frequency was estimated by dividing the number of responding wells by total PBMC plated out(6 xlO 4 cells).
- FIG. 6A illustrates that both CD4+ (CW2F3) and CD8+ (CW1G9, GE1B3 and GE1D6) T cell lines were stimulated specifically by the autologous inoculates but not by the TT-reactive clone. They were potent inhibitors specifically for the inoculates ( Figure 6B) .
- these T cell lines may be classified as anti-clonotypic T cells because of their specific recognition of a clonotypic structure on the MBP specific T-cells in the inoculates (see Lamb et al., Nature 300, 456, 1982; Mohagheghpour et al., J. Exp. Med. 164, 950, 1986; Holoshitz et al. , Science 219, 56, 1983) . It is possible that the anti-clonotypic T cells we obtained represent only a part of the T cell populations induced by the vaccination since the selection was based on their inhibitory effect. Other responding T cells may act by driving the regulation network to enhance the suppression, as typically illustrated by anti-ergotypic T cells isolated from vaccinated experimental animals (Lider et al., Science 239, 181, 1988).
- Figure 6 represents the functional properties of the anti-clonotypic T cell lines.
- Panel A anti- clonotypic T cell lines, tested as responders, were plated out in triplicates at 2 x 10 4 cells /ml and cultured with 4 x IO 4 autologous inoculates or TT- specific T cells as stimulators, which were irradiated (8,000 rads) to prevent their own proliferation. The CPM of the irradiated stimulators did not exceeded 1,200.
- Panel B anti-clonotypic T cell lines were irradiated and used as inhibitors.
- 10 4 cells were added in triplicates to wells containing 10 4 cells from the inoculates or TT-specific T cells and 10 5 APC pulsed with MBP or TT in a proliferation assay. The percentage of inhibition was calculated as specified in Figure 5.
- Panel C the inoculates or TT-specific T cells were labeled with 200 ⁇ Ci 51 Cr for 45 min. , subsequently washed four times and used as target cells in a standard chromium-release assay. After four-hours of incubation, supernatants were harvested and the radioactivity was measured. The effector (anti- clonotypic T cells) to target (the inoculates and control T cells) ratio was eight.
- the maximum and spontaneous releases of chromium were determined in wells containing detergent or medium alone. The percentage of specific cytolysis was calculated as ((experimental release - spontaneous release) / (maximum release - spontaneous release)) x 100.
- Panel D three anti-clonotypic clones were tested for antibody blocking in a chromium release assay. The antibodies used were either directede against class I molecules (W6/32) or against class II molecules (HB55) .
- AHF4.2 was a CD4+ cytotoxic T cell clone specific for MBP-pulsed target cells used as a control. Effector clones were pre incubated with indicated antibodies at 10 ⁇ g /ml for 30 min. before mixing with 51 Cr-labeled target cells. The effector to target ratio was eight, e. Monitoring of clinical improvement and possible toxic effects induced by T cell vaccination
- the responses to the vaccine clones were determined in proliferation assays, in which peripheral blood mononuclear cells (PBMC) were cultured with irradiated vaccine clones.
- the proliferative responses were calculated as stimulation indices (proliferation of PBMC in the presence of vaccine clones/the sum of spontaneous proliferation of PBMC alone and residual proliferation of irradiated vaccine clones) .
- Data are given as mean stimulation indices of seven assays after each inoculation.
- the frequency of MBP-reactive T cells was estimated according to the method described in ref. 25. The frequency before vaccination is indicated on the lines, which ranges from 5.8xl0 "7 to ll. ⁇ xlO "6 in these patients.
- MBP-reactive T cells in MS represent a dominant TCR repertoire and depletion of this population(s) eradicates the major responses to MBP.
- a question may be raised as to whether the depletion of a dominant TCR repertoire will lead to the display of a previously cryptic epitope(s) substitutive for the lost repertoire.
- MBP- reactive T cells have not been found in the vaccinated patients two years after vaccination using the whole MBP molecule as a probe, this possibility can not be ruled out as they may emerge after some time with a different label (different epitope reactivity and V gene usage) .
- the study suggests that the anticlonotypic T cells recognizing MBP-reactive T cells are pre-existing and occur at a rather low frequency in MS patients prior to vaccination.
- the responses are boosted by each inoculation and their frequency mounts typically to a ten-fold increase after the second and the third vaccination.
- it is important to further address the questions as to whether the anticlonotypic T cell responses are consistently low in MS patients and whether they are associated with hyperactivity of MBP-reactive T cells in the disease.
- the molecular identity of the target sequence(s) that triggers the anticlonotypic T cells at least tow variable regions have been mapped so far using a panel of CD8 + MHC class I-restricted anti ⁇ clonotypic T cells isolated from three vaccinated patients ( Figure 10) .
- the anti-clonotypic T cell clones with this recognition pattern responded specifically to the immunizing MBP- specific T cell clone but not to a total of 18 other autologous and MHC-matched allogeneic MBP-specific T cell clones not used for vaccination.
- the other pattern is associated with a clonotypic marker relatively conserved within the V ⁇ region among autologous T cells. This is evident by their reactivity, in addition to the immunizing T cell clones, to other autologous and MHC-matched allogeneic MBP-specific T cells bearing the same V ⁇ sequences.
- the CDR3 recognition pattern seems to be the dominant one and is highly specific for the immunizing clones.
- T cell vaccination could be generalized using a peptide(s) to a category of patients whose targeted autoreactive T cells share a common TCR structural feature.
- a more generalized form of T cell vaccination can depend on its simplified version that takes the advantage of using synthetic peptides or related T cell membrane fractions containing a desired target sequence(s) .
- the CDR2 region sequence is relatively conserved, implying that it is shared by a category of individuals.
- the V ⁇ CDR2 sequences may have more limited heterogeneity as compared to its V ⁇ coutnerparts.
- a library of "made-to-fit" peptides may be generated and a particular "off-shelf" peptide can be selected to attack a given CDR2 or a related sequence shared by the clonally expanded autoreactive T cells in a group of patients.
- a CDR3 region sequence is known to be highly diverse from clone to clone.
- a potential use of similar strategy relies solely on the possibility that the target sequences of the CDR3 recognition pattern may display limited motifs within the V-D-J regions and these sequence motifs may constitute a common epitope(s) for clonotypic interaction. Indeed, such limited V-D-J sequence motifs have been identified among T cells specific for the 89-106 region (one of the immunodominant regions) of human MBP and these common motifs are rather consistent among 89-106 reactive T cells, irrespective of their host origins, f. Cloning of anti-clonotypic T cells.
- Anti ⁇ clonotypic T cell clones derived from this cloning procedure are highly proliferative to the irradiated inoculates and other T cell stimuli and can be further expanded to more than IO 7 - 10 8 cells by adding rIL-2 at each cell passage.
- Table III illustrates a typical experiment in cloning of anti-clonotypic T cell lines.
- TTL tumor specific lymphocytes
- Tumors excised from patients were immediately transported from the hospital to the laboratory. They were then minced into 1-2 mm pieces and subsequently treated with an enzymatic solution containing hyaluronidase type V 0.01%, collagenase type IV 0.1% (Sigma, Vel, Belgium), DNase type I 0.002%, gentamicin 50 ⁇ g/ml and fungizone 250 ng/ml dissolved in RPMI 1640 medium (Gibco, Life technologies, Belgium) . The mixture was incubated for 2-4 hours at 37°C or overnight at room temperature.
- rIL-2 was added at a final concentration of 200 U/ml (Eurocetus) .
- 200 U/ml of lL2 obtained from Eurocetus equals to 5 U/ml obtained from Bochringer Manheim (Germany) (Zhang et al. J.
- TSL were cultured in 24-well plates (Costar, ElsColab, Belgium) in 2 ml aliquots the first 4 weeks and then after dividing the aliquots in two equal parts cultured in the absence or presence of oxidized PBL (see below) in 24-well or 12- well plates.
- TSL tumor specific lymphocytes
- APC antigen-presenting cells
- Oxidation of PBL was performed according to Novogrodsky and Fleischer. Briefly, irradiated allogeneic PBL (4xl0 7 -6 x IO 7 cells/ml) from normal subjects were incubated with galactose oxidase 0.05 U/ml (Sigma) and neuraminidase 0.02 U/ml (Boehringer Mannheim, Germany) in RPMI 1640 medium for 90 min. at 37°C and shaken at 15 min. intervals to prevent formation of clumps. The cells were washed three times with RPMI 1640 containing 0.01 M galactose (Sigma) to block the residual effects of galactose oxidase.
- Oxidized PBL were added to TSL cultures mentioned above at a ratio of 5-10 oxidized PBL to 1 TSL. Cells were restimulated on a weekly basis with oxidized PBL in culture medium containing fresh rIL-2, and viable cell concentrations were returned to 0.5 x IO 6 cells/ml at each passage.
- TSL cell lines were then characterized as to their proliferative response to autologous and allogeneic tumor targets and their cytotoxic activity against the tumor targets.
- FIG. 7 shows the proliferative response of TSL lines to autologous and allogeneic tumor targets.
- IO 4 cells of each TSL line were cultured in triplicate in the presence of 10 5 irradiated PBMC and autologous or allogeneic tumor cells, respectively.
- Microcultures were then pulsed with 1 ⁇ Ci of [ 3 H]-thymidine (Radioche ical Center, Amersham, England) per well 4 hours prior to harvesting and thymidine uptake was measured by liquid scintillation counting.
- Figure 8 represents the cytotoxic activity of the TSL lines against autologous and allogeneic tumor cells, NK-sensitive K562 cell line, and NK-resistant Daudi cell line.
- Target cells were labeled with 200 ⁇ Ci 51 Cr(Na 2 Cr 3 0 4 , Amersham, England) for 60 min. at 37°C and washed four times with medium. Target cells were reincubated for another 30 min. and washed twice before use. 5 x 10 3 labeled target cells were incubated with TSL in 96-well plates in triplicate at various effector:target ratios in a total of 200 ⁇ l volume.
- TIL lines are cloned by limiting dilution at 0.1 cell, 0.3 cell and 1 cell per well in the presence of irradiated allogeneic PBMC and 2 ⁇ g PHA/ml. Cultures are refed with fresh culture medium containing r-IL-2 (5 units/ml) every three days. At Day 14, growth-positive clones (usually 8 - 10% positive rate) are tested for their specific cytotoxic activity against autologous tumor targets in a standard chromium-release assay as described above.
- Tetanus Toxoid (TT) specific T cell lines were generated as described for MBP-specific T cell lines in 1-a.
- the concentration of Tetanus Toxoid antigen used was 2.5 Lf TT per ml.
- TT Tetanus toxoid
- Tetanus toxoid (TT) specific T cells were cloned with the procedure described in 1-b.
- Technically TT-specific T cells are plated out at 0.1 cell and 0.3 cells per well in the presence of autologous or allogeneic PBMC and PHA at 2 ⁇ g/ml.
- TT-specific T cell clones derived from this cloning are highly proliferative to Tetanus Toxoid and other T cell stimuli and can be further expanded to more than IO 7 - IO 9 cells by adding rIL-2 at each cell passage. This method has similar advantages over conventional cloning by TT stimulation as specified in 1-b.
- T-cell lines The same procedures can be applied for the generation of T-cell lines and the isolation of T cell monoclones that are specific for other antigens such as allergens which are responsible for T cell mediated allergies.
- the expanded T-cell monoclones, specific for T-cell mediated allergies, can be used for the treatment of these allergies by applying the same vaccination procedure as specified in 1-c.
- T cell line growth-positive specific clones (% specific cytolysis) / total culture wells / growth-positive
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU63761/94A AU6376194A (en) | 1993-05-14 | 1994-03-10 | Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer |
EP94911145A EP0698087A1 (en) | 1993-05-14 | 1994-03-10 | Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer |
JP6524846A JPH09500261A (en) | 1993-05-14 | 1994-03-10 | Human T cell monoclones, methods for their production and their use in the diagnosis of infectious diseases, autoimmune diseases, T cell mediated allergies and cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93870081.2 | 1993-05-14 | ||
EP93870081 | 1993-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994026876A1 true WO1994026876A1 (en) | 1994-11-24 |
Family
ID=8215343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/000742 WO1994026876A1 (en) | 1993-05-14 | 1994-03-10 | Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0698087A1 (en) |
JP (1) | JPH09500261A (en) |
AU (1) | AU6376194A (en) |
CA (1) | CA2162853A1 (en) |
IL (1) | IL108926A0 (en) |
WO (1) | WO1994026876A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0896999A1 (en) * | 1996-03-13 | 1999-02-17 | Shionogi & Co., Ltd. | Human t cell clone specific for rheumatoid arthritis |
US7658926B2 (en) | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
US7695713B2 (en) | 2002-08-08 | 2010-04-13 | Baylor College Of Medicine | Isolation and identification of T cells |
US10787642B2 (en) | 2010-02-03 | 2020-09-29 | The University Of Tokyo | Method for reconstructing immune function using pluripotent stem cells |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2011096482A1 (en) * | 2010-02-03 | 2013-06-13 | 国立大学法人 東京大学 | Immune function reconstruction using pluripotent stem cells |
JP6025707B2 (en) * | 2010-04-06 | 2016-11-16 | エクソサイト セラピューティクス ピーティイー リミテッド | How to treat cancer |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985003948A1 (en) * | 1984-03-02 | 1985-09-12 | Celltech Limited | Macrophage activating factor |
EP0203403A2 (en) * | 1985-05-01 | 1986-12-03 | Asahi Kasei Kogyo Kabushiki Kaisha | A cloned T cell capable of recognizing tumors and a T cell antigen receptor |
EP0362755A2 (en) * | 1988-10-03 | 1990-04-11 | Asahi Kasei Kogyo Kabushiki Kaisha | Human cytotoxic t-cell clone and antibody thereto |
WO1990011294A1 (en) * | 1989-03-21 | 1990-10-04 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
WO1992021367A1 (en) * | 1991-05-31 | 1992-12-10 | Arthur Allen Vandenbark | T cell receptor peptides as therapeutics for immune-related disease |
-
1994
- 1994-03-10 AU AU63761/94A patent/AU6376194A/en not_active Abandoned
- 1994-03-10 IL IL10892694A patent/IL108926A0/en unknown
- 1994-03-10 CA CA002162853A patent/CA2162853A1/en not_active Abandoned
- 1994-03-10 EP EP94911145A patent/EP0698087A1/en not_active Withdrawn
- 1994-03-10 WO PCT/EP1994/000742 patent/WO1994026876A1/en not_active Application Discontinuation
- 1994-03-10 JP JP6524846A patent/JPH09500261A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985003948A1 (en) * | 1984-03-02 | 1985-09-12 | Celltech Limited | Macrophage activating factor |
EP0203403A2 (en) * | 1985-05-01 | 1986-12-03 | Asahi Kasei Kogyo Kabushiki Kaisha | A cloned T cell capable of recognizing tumors and a T cell antigen receptor |
EP0362755A2 (en) * | 1988-10-03 | 1990-04-11 | Asahi Kasei Kogyo Kabushiki Kaisha | Human cytotoxic t-cell clone and antibody thereto |
WO1990011294A1 (en) * | 1989-03-21 | 1990-10-04 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
WO1992021367A1 (en) * | 1991-05-31 | 1992-12-10 | Arthur Allen Vandenbark | T cell receptor peptides as therapeutics for immune-related disease |
Non-Patent Citations (3)
Title |
---|
A.BEN-NUN ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 88, March 1991 (1991-03-01), WASHINGTON US, pages 2466 - 2470 * |
J. ZHANG ET AL., ANNALS OF NEUROLOGY, vol. 32, no. 3, 1992, BOSTON US, pages 330 - 338 * |
K.OTA ET AL., NATURE., vol. 346, 12 July 1990 (1990-07-12), LONDON GB, pages 183 - 187 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0896999A1 (en) * | 1996-03-13 | 1999-02-17 | Shionogi & Co., Ltd. | Human t cell clone specific for rheumatoid arthritis |
EP0896999A4 (en) * | 1996-03-13 | 2001-03-14 | Shionogi & Co | Human t cell clone specific for rheumatoid arthritis |
US7658926B2 (en) | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
US7695713B2 (en) | 2002-08-08 | 2010-04-13 | Baylor College Of Medicine | Isolation and identification of T cells |
US10787642B2 (en) | 2010-02-03 | 2020-09-29 | The University Of Tokyo | Method for reconstructing immune function using pluripotent stem cells |
Also Published As
Publication number | Publication date |
---|---|
EP0698087A1 (en) | 1996-02-28 |
AU6376194A (en) | 1994-12-12 |
CA2162853A1 (en) | 1994-11-24 |
JPH09500261A (en) | 1997-01-14 |
IL108926A0 (en) | 1994-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jiang et al. | The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1 | |
Shevach | CD4+ CD25+ suppressor T cells: more questions than answers | |
EP0552142B1 (en) | T cell receptor peptides as therapeutics for autoimmune and malignant disease | |
RU2327487C2 (en) | Release and identification of t-cells | |
JP6000205B2 (en) | T cell vaccine | |
AU7112098A (en) | Dendritic cell hybrids | |
AU674494B2 (en) | T cell receptor peptides as therapeutics for immune-related disease | |
AU755884B2 (en) | T-cell vaccination for the treatment of multiple sclerosis | |
Hermans et al. | Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination | |
WO1994026876A1 (en) | Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer | |
Zhang et al. | T cell vaccination: clinical application in autoimmune diseases | |
WO1999027957A1 (en) | Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides | |
JP2004208548A (en) | Antigen-specific suppression of immunoreaction | |
AU764015C (en) | Ex vivo treatment of allogeneic and xenogeneic T-cells with gp39 antagonists | |
Zhang | T-cell vaccination in multiple sclerosis: immunoregulatory mechanism and prospects for therapy | |
RU2209633C2 (en) | T-cellular vaccine for cerebrospinal sclerosis treatment | |
LIN et al. | The treatment of autoimmune disease in (NZB/NZW) F1 mice with syngeneic photomodulated splenocytes | |
AU2003261499B2 (en) | Ex vivo treatment of allogeneic and xenogeneic T-cells with gp39 antagonists | |
Han et al. | Isolation and functional analysis of autoreactive T cells from BXSB mice with murine lupus | |
KR100304042B1 (en) | T cell receptor peptides as therapeutics for immune-related disease | |
US20200061112A1 (en) | Dendritic Cells as a Novel Delivery System for Immunotherapy | |
Skinner et al. | T Cell Vaccination in Autoimmune Disease | |
JP2002539271A (en) | Induction of antigen-specific non-responsiveness by glioblastoma culture supernatant (GCS) | |
Stinissen et al. | AUTOREACTIVE T LYMPHOCYTES IN MULTIPLE SCLEROSIS | |
Miller et al. | T-cell vaccination and antigen-driven immunotherapy for multiple sclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994911145 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2162853 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1994911145 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1996 549782 Country of ref document: US Date of ref document: 19960305 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994911145 Country of ref document: EP |